Benchmark initiates Semler Scientific stock with Buy rating on bitcoin strategy
Investing.com
Published Jul 08, 2025 07:50AM ET
Investing.com - Benchmark initiated coverage on Semler Scientific (NASDAQ:SMLR) with a Buy rating and a price target of $101.00 on Tuesday. The stock, currently trading at $38.95, shows significant upside potential, with other analysts targeting $71.00. According to InvestingPro data, the company maintains impressive gross profit margins of 91%.
The research firm cited Semler's recent strategic pivot to adopt bitcoin as its primary treasury reserve asset as a key factor in its positive outlook for the healthcare company.
Semler Scientific, which spent over 15 years focused on chronic disease detection in aging and at-risk populations, made this significant change on May 28, 2024.
The company has become only the second publicly traded U.S. company to refocus its operations around the accumulation of bitcoins, following the strategy of MicroStrategy.
Benchmark noted that Semler is following the "playbook" of Strategy (MSTR), which the firm currently rates as Buy with a $650 price target.
In other recent news, Semler Scientific, Inc. has formed a new subsidiary, CardioVanta, Inc., to focus on early detection of heart failure and cardiac arrhythmia monitoring. The company plans to operate CardioVanta under a software-as-a-service model and is seeking external investment to fund its initial capital needs. Semler Scientific has reported raising approximately $114.8 million through the sale of 3,003,488 shares of its common stock, which is part of its capital allocation strategy. Proceeds from these stock sales have been partly used to acquire 455 Bitcoin, increasing its total holdings to 4,264 Bitcoin. In a strategic move, Semler Scientific has appointed Natalie Brunell to its Board of Directors, who will also join the Bitcoin Strategy Committee. Brunell is a well-known figure in the Bitcoin community and brings significant expertise to support the company's Bitcoin initiatives. Additionally, Semler Scientific continues to market its QuantaFlo device, which aids in diagnosing cardiovascular diseases. These developments highlight the company's dual focus on advancing cardiac health technologies and expanding its presence in the cryptocurrency space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.